Kowalewski Adam, Zdrenka Marek, Grzanka Dariusz, Szylberg Łukasz
Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-067 Bydgoszcz, Poland.
Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland.
Cancers (Basel). 2020 Nov 9;12(11):3300. doi: 10.3390/cancers12113300.
The emergence of clinical resistance to currently available systemic therapies forces us to rethink our approach to clear cell renal cell carcinoma (ccRCC). The ability to influence ccRCC evolution by inhibiting processes that propel it or manipulating its course may be an adequate strategy. There are seven deterministic evolutionary trajectories of ccRCC, which correlate with clinical phenotypes. We suspect that each trajectory has its own unique weaknesses that could be exploited. In this review, we have summarized recent advances in the treatment of ccRCC and demonstrated how to improve systemic therapies from the evolutionary perspective. Since there are only a few evolutionary trajectories in ccRCC, it appears feasible to use them as potential biomarkers for guiding intervention and surveillance. We believe that the presented patient stratification could help predict future steps of malignant progression, thereby informing optimal and personalized clinical decisions.
目前可用的全身治疗出现临床耐药性,迫使我们重新思考对透明细胞肾细胞癌(ccRCC)的治疗方法。通过抑制推动ccRCC发展的过程或操纵其进程来影响ccRCC演变的能力可能是一种合适的策略。ccRCC有七种确定性的进化轨迹,它们与临床表型相关。我们怀疑每条轨迹都有其自身独特的弱点,可以加以利用。在本综述中,我们总结了ccRCC治疗的最新进展,并展示了如何从进化角度改进全身治疗。由于ccRCC的进化轨迹较少,将其用作指导干预和监测的潜在生物标志物似乎是可行的。我们相信,所提出的患者分层有助于预测恶性进展的未来步骤,从而为最佳和个性化的临床决策提供依据。